c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

INTRODUCTION: Bevacizumab improves survival outcomes in women diagnosed with epithelial ovarian cancer (EOC). Pre-clinical data showed that the c-MET/VEGFR-2 heterocomplex negates VEGF inhibition through activation of c-MET signalling, leading to a more invasive and metastatic phenotype. We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Robert D., Ferreras, Cristina, Peset, Isabel, Avizienyte, Egle, Renehan, Andrew G., Edmondson, Richard J., Murphy, Alexander D., Nicum, Shibani, Van Brussel, Thomas, Clamp, Andrew R., Lambrechts, Diether, Zhou, Cong, Jayson, Gordon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832801/
https://www.ncbi.nlm.nih.gov/pubmed/35144591
http://dx.doi.org/10.1186/s12916-022-02270-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832801/
https://www.ncbi.nlm.nih.gov/pubmed/35144591
http://dx.doi.org/10.1186/s12916-022-02270-y

Ejemplares similares